SITAGLIPTIN GENERINOBEL 25mg tablets medication leaflet

A10BH01 sitagliptin • Alimentary tract and metabolism | Blood glucose lowering drugs, excl. insulins | Dipeptidyl peptidase 4 (DDP-4) inhibitors

Sitagliptin is a medication used to treat type 2 diabetes. It belongs to the class of dipeptidyl peptidase-4 (DPP-4) inhibitors, which work by increasing the levels of incretin hormones. These hormones stimulate insulin secretion and reduce glucagon production, thereby lowering blood sugar levels, especially after meals.

Sitagliptin is taken orally, usually once daily, with or without food. It is used either as monotherapy or in combination with other antidiabetic medications, such as metformin or sulfonylureas, to improve glycemic control.

Common side effects include headaches, upper respiratory tract infections, nasal congestion, and abdominal pain. In rare cases, it may cause more serious reactions, such as pancreatitis, severe allergic reactions (angioedema, urticaria), or severe joint pain.

Sitagliptin is not indicated for the treatment of type 1 diabetes or diabetic ketoacidosis. It is important for patients to follow their doctor's recommendations, regularly monitor blood sugar levels, and report any adverse reactions or changes in health.

General data about SITAGLIPTIN GENERINOBEL 25mg

Substance: sitagliptin

Commercial code: W71178001

Concentration: 25mg

Pharmaceutical form: tablets

Product type: generic

Prescription restrictions: P-RF - Medicines prescription that is retained in the pharmacy (not renewable).

Marketing authorisation

Manufacturer: GENERINOBEL GMBH - GERMANIA

Holder: GENERINOBEL GMBH - GERMANIA

Number: 16072/2025/01

Shelf life: 18 months

Pharmaceutical forms available for sitagliptin

Concentrations available for sitagliptin

100mg, 25mg, 25mg/ml, 50mg, 50mg/1000mg, 50mg/850mg

Other substances similar to sitagliptin